![[🔔 📣 Call for pharmaceutical companies to join in the CDDF Diversity Initiative]](https://cddf.org/wp-content/uploads/2024/09/Copy-of-Copy-of-Copy-of-Dark-Purple-and-Blue-Texture-Blur-Circle-Business-Marketing-Presentation-1080x675.jpg)
[🔔 📣 Call for pharmaceutical companies to join in the CDDF Diversity Initiative]
We are delighted to announce that the Cancer Drug Development Forum (CDDF) has launched its initiative on diversity in oncology clinical trials. CDDF cordially invites pharmaceutical companies to participate in this collaborative effort to support the planning and...
ACT EU: Stakeholder Presentation on Critical Use-Cases at MSP Advisory Group Meeting (4 July 2024)
On 4 July 2024, CDDF participated in a stakeholder presentation focused on critical use-cases at Multi-Stakeholder Platform (MSP) Advisory Group meeting. The session aimed to identify and discuss real-world challenges faced by stakeholder groups within the European...![[🔔 📢 Key Takeaways from the CDDF Webinar on “Bayesian Approaches in Drug Development”]](https://cddf.org/wp-content/uploads/2024/07/Capture-4-1080x675.jpg)
[🔔 📢 Key Takeaways from the CDDF Webinar on “Bayesian Approaches in Drug Development”]
The Cancer Drug Development Forum (CDDF) held a live webinar on Bayesian Approaches in Drug Development on 11 July 2024. In this webinar, Rob Hemmings (Consilium) gave an insightful talk followed by a Q&A discussion moderated by Axel Glasmacher (CDDF) and Eva...